<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5414">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03036462</url>
  </required_header>
  <id_info>
    <org_study_id>FAIR-HF2</org_study_id>
    <secondary_id>FAIR-HF2-DZHK5</secondary_id>
    <nct_id>NCT03036462</nct_id>
  </id_info>
  <brief_title>Intravenous Iron in Patients With Systolic Heart Failure and Iron Deficiency to Improve Morbidity &amp; Mortality</brief_title>
  <acronym>FAIR-HF2</acronym>
  <official_title>Intravenous Iron in Patients With Systolic Heart Failure and Iron Deficiency to Improve Morbidity &amp; Mortality - FAIR-HF2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Göttingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether intravenous iron supplementation using
      ferric carboxymaltosis (FCM) reduces hospitalisation and mortality in patients with iron
      deficiency and heart failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The clinical trial is designed as an international, prospective, multi-centre, double-blind,
      parallel group, randomised, controlled, interventional trial to investigate whether a
      long-term therapy with i.v. iron (ferric carboxymaltosis) compared to placebo can reduce the
      rate of recurrent heart failure hospitalisations and cardiovascular (CV) death in patients
      with heart failure with reduced ejection fraction (HFrEF).

      I.v. iron administration in the form of ferric carboxymaltosis (FCM) will be carried out
      according to the Summary of Product Characteristics (SmPC). Bolus administration (1000 mg)
      will be followed by an optional administration of 500-1000 mg within the first 4 weeks (up
      to a total of 2000 mg which is in-label) according to approved dosing rules, followed by
      administration of 500 mg FCM at every 4 months, except when haemoglobin is &gt; 16.0 g/dL or
      ferritin is &gt; 800 µg/L.

      In the verum group, all patients will receive a saline administration, when no iron is
      indicated at the time of the visit and according to the values listed above. Patients
      originally assigned to the placebo group will receive a saline administration at all visits.

      In the control group i.v. NaCl at a volume according to the dosing rules for FCM at all
      visits will be administered in a double-blind manner.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 7, 2017</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combined rate of recurrent hospitalisations for heart failure (HF) and of cardiovascular death (number of events)</measure>
    <time_frame>at least after 12 month of follow-up</time_frame>
    <description>Combined rate of recurrent hospitalisations for heart failure and of cardiovascular death during follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Combined rate of recurrent cardiovascular hospitalisations and of cardiovascular death (number of events)</measure>
    <time_frame>at least after 12 month of follow-up</time_frame>
    <description>Combined rate of recurrent cardiovascular hospitalisations and of cardiovascular death during follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined rate of recurrent hospitalisations for any reason and of cardiovascular death (number of events)</measure>
    <time_frame>at least after 12 month of follow-up</time_frame>
    <description>Combined rate of recurrent hospitalisations for any reason and of cardiovascular death during follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of recurrent cardiovascular hospitalisations (number of events)</measure>
    <time_frame>at least after 12 month of follow-up</time_frame>
    <description>Rate of recurrent cardiovascular hospitalisations during follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of recurrent HF hospitalisations (number of events)</measure>
    <time_frame>at least after 12 month of follow-up</time_frame>
    <description>Rate of recurrent HF hospitalisations during follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of recurrent hospitalisations of any kind (number of events)</measure>
    <time_frame>at least after 12 month of follow-up</time_frame>
    <description>Rate of recurrent hospitalisations of any kind during follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality (number of events)</measure>
    <time_frame>at least after 12 month of follow-up</time_frame>
    <description>All-cause mortality during follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiovascular mortality (number of events)</measure>
    <time_frame>at least after 12 month of follow-up</time_frame>
    <description>cardiovascular mortality during follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in NYHA (New York Heart Association) functional class (scale)</measure>
    <time_frame>at least after 12 month of follow-up</time_frame>
    <description>Changes in NYHA functional class during follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in 6-minute walk-test (nomogram)</measure>
    <time_frame>at least after 12 month of follow-up</time_frame>
    <description>Changes in 6-minute walk-test during follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in EQ-5D (questionnaire)</measure>
    <time_frame>at least after 12 month of follow-up</time_frame>
    <description>Changes EQ-5D during follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Patient Global Assessment (PGA) of wellbeing (questionnaire)</measure>
    <time_frame>at least after 12 month of follow-up</time_frame>
    <description>Changes in PGA of wellbeing during follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in renal parameters (laboratory parameters)</measure>
    <time_frame>at least after 12 month of follow-up</time_frame>
    <description>Changes in renal from baseline to end of follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in cardiovascular parameters (laboratory parameters)</measure>
    <time_frame>at least after 12 month of follow-up</time_frame>
    <description>Changes in cardiovascular parameters from baseline to end of follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in inflammatory parameters (laboratory parameters)</measure>
    <time_frame>at least after 12 month of follow-up</time_frame>
    <description>Changes in inflammatory parameters from baseline to end of follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in metabolic parameters (laboratory parameters)</measure>
    <time_frame>at least after 12 month of follow-up</time_frame>
    <description>Changes in metabolic parameters from baseline to end of follow-up</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Systolic Heart Failure</condition>
  <condition>Iron Deficiency</condition>
  <arm_group>
    <arm_group_label>Verum group (FCM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>I.v. iron administration in the form of FCM will be carried out according to SmPC. I.v. iron bolus administration (1000 mg) will be followed by an optional administration of 500-1000 mg within the first 4 weeks, (up to a total of 2000 mg which is in-label), according to the approved dosing rules, followed by administration of 500 mg FCM at every 4 months, except when haemoglobin is &gt; 16.0 g/dL or ferritin is &gt; 800 µg/L .In the verum group, all patients will receive a saline administration, when no iron is indicated at the time of the visit and according to the values listed above.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group (NaCL)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administration of i.v. NaCl at a volume according to the dosing rules for FCM, i.e. as described for the verum group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iron</intervention_name>
    <description>i.v. iron administration</description>
    <arm_group_label>Verum group (FCM)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>i.v. NaCl administration</description>
    <arm_group_label>Placebo group (NaCL)</arm_group_label>
    <other_name>salin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged at least 18 years

          -  Patients with chronic heart failure present for at least 12 months

          -  Confirmed presence of iron deficiency

          -  Serum haemoglobin of 9.5 to 14.0 g/dL

        Exclusion Criteria:

          -  Hypersensitivity to the active substance, to FCM or any of its excipients

          -  Known serious hypersensitivity to other parenteral iron products

          -  Anaemia not attributed to iron deficiency, e.g. other microcytic anaemia

          -  Evidence of iron overload or disturbances in the utilisation of iron
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mahir Karaks, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Hamburg-Eppendorf</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mahir Karakas, MD</last_name>
    <email>m.karakas@uke.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stefan Anker, MD</last_name>
    <email>s.anker@cachexia.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kerckhoff Klinik Bad Nauheim</name>
      <address>
        <city>Bad Nauheim</city>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian W Hamm, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Berlin Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David M Leistner, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charité Berlin (Campus Virchow-Klinikum)</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frank Edelmann, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Göttingen</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefan Anker, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitärsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20251</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mahir Karakas, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lutz Frankenstein, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlandes</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ingrid Kindermann, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mark Luedde, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein Campus Lübeck</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Holger Thiele, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexander Schmeißer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin der Johannes Gutenberg-Universität Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tommaso Gori, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christina Dösch, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Hagenmiller/ Jeserich</name>
      <address>
        <city>Nürnberg</city>
        <zip>90402</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Jeserich, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jochen Woehrle, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Evangelisches Klinikum Witten</name>
      <address>
        <city>Witten</city>
        <zip>58455</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tomas Horacek, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szent Imre Kórház</name>
      <address>
        <city>Budapest</city>
        <zip>1115</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zoltán Járai</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bela Merkely, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szent János kórház és Észak-budai Egyesített kórházak</name>
      <address>
        <city>Budapest</city>
        <zip>1125</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rita Kazinczy, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Honvéd Kórház</name>
      <address>
        <city>Budapest</city>
        <zip>1134</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Róbert G Kiss, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pécsi Orvostudományi</name>
      <address>
        <city>Pecs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kálmán Tóth, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de la Luz</name>
      <address>
        <city>Lisbon</city>
        <zip>1500-650</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pedro Moraes Sarmento, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Santa Maria University Hospital</name>
      <address>
        <city>Lisbon</city>
        <zip>1649-028</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dulce Brito, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Fausto Pinto, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Josep Comin Colet, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Clinico San Carlos Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ramon Bover, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitarion Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jose M Garcia Pinilla, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julio Nuñez Villota, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital la Fe de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luis Almenar Bonet, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Portugal</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 21, 2017</lastchanged_date>
  <firstreceived_date>September 15, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>intravenous iron</keyword>
  <keyword>systolic heart failure</keyword>
  <keyword>iron deficiency</keyword>
  <keyword>morbidity</keyword>
  <keyword>mortality</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
    <mesh_term>Heart Failure, Systolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Iron</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
